Redeye takes a neutral view on Addnode following a solid Q4 report.
5.2% organic sales growth, improving margins EBITDA up 1.
Redeye continue to see an exciting case in Nanologica despite the Q4 report falling short of sales a...
Redeye shares its preview of Sedana Medical’s Q4 2023e results, due February 15.
Q4 EBIT -100mkr Q4 påverkades kraftigt negativt av låga massapriser, höga råvarupriser och underhåll...
Market-leading white-label software provider for takeaway restaurants 13% ARR CAGR and 11pp EBITDA m...
Redeye gives its initial take on Kontigo Care’s Q4 2023 report, which came in slightly softer than w...
DT’s Q4 results topped estimates as costs remained under control while SBU continued to drive growth...
Consti's net sales in Q4 amounted to EUR 86.1m, below our estimates (Evli est.
SRV’s current low risk backlog will support it through the tougher market with hopes for higher marg...
Redeye provides its initial take on Lifco’s Q4 2023 report, which came in slightly below our estimat...
Sales and EBITDA inline with pre-announcement 31% organic growth in Technology Estimates likely up 1...
Hansa’s actual outcome after the trading outcome confirms that Idefirix records European product sal...
Redeye updates on Evolution post Q4-results which came in close to our forecasts.
We cut '24e-'25e EBITA by 9-6% Margin recovery likely to be driven by better sales mix Trading at '2...
Redeye was impressed by yet another solid quarter from new-old CEO, Anders Lidbeck, who once again b...
2023 was a weak year for the dry bulk sector, reflected in ESL Shipping's clean EBIT declining by 50...
Redeye comments on the public offering announced today.
Redeye is neutral about the return of the lipodystrophy project, as it does not affect our base case...